| Net Cash Provided by (Used in) Operating Activities |
$594,147 |
USD |
-239% |
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Financing Activities |
$6,610 |
USD |
-93% |
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Investing Activities |
$1,175,644 |
USD |
-101% |
Q1 2024 |
Q1 2024 |
| Common Stock, Shares Authorized |
490,000,000 |
shares |
|
Q3 2025 |
Q3 2025 |
| Common Stock, Shares, Issued |
41,959,958 |
shares |
|
Q3 2025 |
Q3 2025 |
| Common Stock, Par or Stated Value Per Share |
0 |
USD/shares |
|
Q3 2025 |
Q3 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
$587,537 |
USD |
-680% |
Q1 2025 |
Q1 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$11,810 |
USD |
-96% |
Q3 2024 |
Q3 2024 |
| Deferred Tax Assets, Valuation Allowance |
$2,240,166 |
USD |
143% |
Q4 2024 |
FY 2024 |
| Deferred Tax Assets, Gross |
$2,240,166 |
USD |
143% |
Q4 2024 |
FY 2024 |
| Deferred Income Tax Expense (Benefit) |
$422 |
USD |
|
Q1 2024 |
Q1 2024 |
| Deferred Tax Assets, Operating Loss Carryforwards |
$2,240,166 |
USD |
143% |
Q4 2024 |
FY 2024 |
| Preferred Stock, Shares Authorized |
8,500,000 |
shares |
750% |
Q3 2025 |
Q3 2025 |
| Unrecognized Tax Benefits |
$0 |
USD |
|
Q3 2024 |
Q3 2024 |
| Additional Paid in Capital |
$49,610,004 |
USD |
3575% |
Q3 2025 |
Q3 2025 |
| Preferred Stock, Par or Stated Value Per Share |
0 |
USD/shares |
0% |
Q3 2024 |
Q3 2024 |